Literature DB >> 17607899

Major T-cell responses in multiple sclerosis.

L Steinman1, A Waisman, D Altmann.   

Abstract

Evidence is emerging that the major T- and B-cell response in multiple sclerosis (MS) is directed to a region of myelin basic protein (MBP) between residues 84 and 103. In rodent models of MS, immunization to this component of MBP evokes experimental autoimmune encephalomyelitis (EAE). T cells found in EAE lesions show similarities in the VJ and VDJ regions of their alpha and beta chains with T cells in MS lesions, and with T cells that are specific for MBPp84-103 isolated from patients with MS. If this region of MBP is critical in the pathogenesis of MS, then therapy aimed at controlling the immune response to this immunodominant region of MBP may be beneficial in treating MS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 17607899     DOI: 10.1016/s1357-4310(95)92366-7

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  9 in total

Review 1.  Antigen specific immunotherapy of multiple sclerosis.

Authors:  L Steinman; P Conlon
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

2.  Multiple sclerosis-associated virus-related pol sequences found both in multiple sclerosis and healthy donors are more frequently expressed in multiple sclerosis patients.

Authors:  Jerzy Nowak; Danuta Januszkiewicz; Monika Pernak; Izabela Liweń; Mariola Zawada; Jolanta Rembowska; Karina Nowicka; Krzysztof Lewandowski; Hanna Hertmanowska; Mieczyslaw Wender
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

3.  Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features.

Authors:  K G Warren; I Catz; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

4.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

5.  Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope.

Authors:  Abdiwahab A Musse; Joan M Boggs; George Harauz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-09       Impact factor: 11.205

6.  Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system.

Authors:  Chiara Cordiglieri; Francesca Odoardi; Bo Zhang; Merle Nebel; Naoto Kawakami; Wolfgang E F Klinkert; Dimtri Lodygin; Fred Lühder; Esther Breunig; Detlev Schild; Vijay Kumar Ulaganathan; Klaus Dornmair; Werner Dammermann; Barry V L Potter; Andreas H Guse; Alexander Flügel
Journal:  Brain       Date:  2010-06-02       Impact factor: 13.501

7.  Disturbed distribution of proliferative brain cells during lupus-like disease.

Authors:  Mile Stanojcic; Tal Burstyn-Cohen; Nadia Nashi; Greg Lemke; Boris Sakic
Journal:  Brain Behav Immun       Date:  2009-06-06       Impact factor: 7.217

8.  Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis.

Authors:  Sergey A Shiryaev; Albert G Remacle; Alexei Y Savinov; Andrei V Chernov; Piotr Cieplak; Ilian A Radichev; Roy Williams; Tatiana N Shiryaeva; Katarzyna Gawlik; Tatiana I Postnova; Boris I Ratnikov; Alexei M Eroshkin; Khatereh Motamedchaboki; Jeffrey W Smith; Alex Y Strongin
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

9.  Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis.

Authors:  Sergey A Shiryaev; Alexei Y Savinov; Piotr Cieplak; Boris I Ratnikov; Khatereh Motamedchaboki; Jeffrey W Smith; Alex Y Strongin
Journal:  PLoS One       Date:  2009-03-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.